Are you the publisher? Claim or contact us about this channel

Embed this content in your HTML


Report adult content:

click to rate:

Account: (login)

More Channels


Channel Catalog

Channel Description:

Visit One News Page for Europe news from around the world, aggregated from leading sources including newswires, newspapers and broadcast media. Search millions of archived news headlines. This feed provides the Europe news headlines.

older | 1 | .... | 1586 | 1587 | (Page 1588) | 1589 | 1590 | .... | 1652 | newer

    0 0

    According to the report, the global hybrid fiber optic connectors market accounted for USD 588 million in 2017 and is expected to reach USD 964 million globally by 2024, at a CAGR of around 7.3% between 2018 and 2024.

    New York, NY, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled *“Hybrid Fiber Optic Connectors Market by Attenuation (0.1dB, 0.5dB, 0.75dB, and Others), by Length (Less Than 100mm and More Than 101mm), by Endurance (500 to 2,000 cycles, 2,000 to 20,000 cycles, and More Than 20,000 cycles), and by End-Use Industry (Telecom, Oil & Gas, Aerospace & Defense, Healthcare, Transportation, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017—2024”*. According to the report, the global hybrid fiber optic connectors market accounted for USD 588 million in 2017 and is expected to reach USD 964 million globally by 2024, at a CAGR of around 7.3% between 2018 and 2024.

    Hybrid fiber optic connectors connect fiber cables, to ensure stable connections and proper end-to-end fiber alignment. These connectors are manufactured from stainless steel to resist corrosion when exposed to harsh environmental conditions.

    *Browse through 87 Tables & 33 Figures spread over 146 Pages and in-depth TOC on “Global Hybrid Fiber Optic Connectors Market: Industry Size, Share, Trends, Analysis, and Forecast, 2017—2024”.*

    *Request Free Sample Report of Global Hybrid Fiber Optic Connectors Market Report @ *

    The increasing transportation by airways is likely to fuel the hybrid fiber optic connectors market in the future. These connectors are used for security and control systems for data acquisition and transmission. In 2017, the global commercial airline's sector generated about USD 754 billion in revenue as compared to USD 709 billion in 2016. Furthermore, in 2017, the global number of aircraft fleet was 28,500 as compared to 27,400 in 2016. This number is projected to rise in the future due to growing tourism globally. This, in turn, is anticipated to drive the hybrid fiber optic connectors market globally over the forecast timeframe. The flourishing telecom sector is likely to further fuel the hybrid fiber optic connectors market over the estimated time period. Fiber optics is used by various telecom companies to transmit telecom signals over long distances, cable TV signals, and internet communication. The organizational spending on telecom services has increased over the last few years. In 2017, the global spending on telecom services and paid TV services increased to USD 1,662 billion, about 1.4% more than that in 2016.

    The hybrid fiber optic connectors market is divided based on attenuation, length, endurance, and end-use industry. By attenuation, the market is divided into 0.1dB, 0.5dB, 0.75dB, and others. By length, the market is divided into less than 100mm and more than 101mm. The more than 101mm segment is projected to hold a substantial market share over the forecast time period, due to its increasing adoption in the oil and gas sector. The endurance segment of this market includes 500 to 2,000 cycles, 2,000 to 20,000 cycles, and more than 20,000 cycles. The 2,000 to 20,000 cycles are likely to grow lucratively over the estimated timeframe, due to the huge product demand by the defense sector. By end-use industry, the market is segmented into telecom, oil and gas, aerospace and defense, healthcare, transportation, and others.

    *Download Free Report PDF Brochure: *

    North America is likely to witness considerable growth in the global hybrid fiber optic connectors market over the forecast time period. The U.S. is anticipated to be the most lucrative market in the region, due to the huge production of hybrid fiber optic connectors leveraged by technological advancements. In the Middle East and Africa, UAE and Saudi Arabia are anticipated to drive the region’s hybrid fiber optic connectors market, due to the growing use of connectors in the oil and gas industry.

    The European hybrid fiber optic connectors market is likely to be driven by the flourishing aerospace sector. Since these connectors can operate in harsh conditions and are durable and reliable, they are used for communication. In 2017, the UK aerospace sector generated USD 40.6 billion in revenue, registering about 40% increase over the past five years.

    *Inquire more about this report before purchase @ *

    Asia Pacific is likely to witness significant growth in the global hybrid fiber optic connectors market in the upcoming years, due to the increased product demand by telecom organizations. Fiber optics is used by various telecom companies to transmit signals over long distance and communicate via the internet. India is expected to have a huge growth potential for the hybrid fiber optic connectors market, owing to the rapidly growing country’s telecom sector. In 2018, India is ranked second in terms of internet users and telecom subscribers.

    The Middle Eastern and African region is likely to contribute substantially toward the global hybrid fiber optic connectors market, owing to rapidly prospering oil and gas sector. Fiber optics provides a large bandwidth and can be used for providing data related to oil reserve levels, environmental conditions, and equipment performance. In 2017, petrochemical and oil and gas producers invested about USD 294 billion in various projects in the region. These investments are projected to drive this regional market in the future.

    Browse the full *"Hybrid Fiber Optic Connectors Market by Attenuation (0.1dB, 0.5dB, 0.75dB, and Others), by Length (Less Than 100mm and More Than 101mm), by Endurance (500 to 2,000 cycles, 2,000 to 20,000 cycles, and More Than 20,000 cycles), and by End-Use Industry (Telecom, Oil & Gas, Aerospace & Defense, Healthcare, Transportation, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017—2024"* Report At

    Latin America is expected to contribute to the market for hybrid fiber optic connectors. These connectors are used in varied medical electronic equipment, such as surgical instruments, diagnostic devices, cardiac assist devices, etc. In 2018, Brazil is likely to emerge as the largest healthcare market in the region. The country’s medical device sector is valued at USD 10.8 billion. It imports the majority of medical equipment from the U.S. In 2017, the U.S. medical device exports to Brazil reached almost USD 1 billion, i.e., 2.5% more than in 2016.

    Some key players of the global hybrid fiber optic connectors market are Diamond SA, Amphenol Corporation, LEMO, Hirose Electric Company, Staubli International AG, QPC Fiber Optic, LLC, Smiths Interconnect, Inc., TE Connectivity Corporation, and Teledyne Technologies, Inc., among others.

    *Request customized copy of report @ *

    *This report segments the global hybrid fiber optic connectors market into:*

    *Global Hybrid Fiber Optic Connectors Market: Attenuation Segment *

    · 0.1dB
    · 0.5dB
    · 0.75dB
    · Others

    *Global Hybrid Fiber Optic Connectors Market: Length Segment *

    · Less than 100mm
    · More than 101mm

    *Global Hybrid Fiber Optic Connectors Market: Endurance Segment *

    · 500 to 2,000 cycles
    · 2,000 to 20,000 cycles
    · More than 20,000 cycles

    *Global Hybrid Fiber Optic Connectors Market: End-Use Industry Segment Analysis*

    · Telecom
    · Oil and Gas
    · Aerospace and Defense
    · Healthcare
    · Transportation
    · Others

    *Global Hybrid Fiber Optic Connectors Market: Regional Segment*

    · North America

    · The U.S.

    · Europe

    · UK
    · France
    · Germany

    · Asia Pacific

    · China
    · Japan
    · India

    · Latin America

    · Brazil

    · The Middle East and Africa

    *Related Reports:*

    · *Gas Sensors Market: *
    · *Automation-as-a-Service Market: *
    · *High Voltage Switchgear Market:*
    · *HVAC Controls Market:*
    · *3D TSV Market:*                                      

    *About Us:*

    Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

    *Follow Us LinkedIn: *
    *Follow Us Twitter: *

    *Blog:* |

    *Contact Us:*

    Joel John
    244 Fifth Avenue, Suite N202
    New York, 10001, United States
    Tel: +49-322 210 92714
    USA/Canada Toll-Free No.1-855-465-4651


    *Blog:* Reported by GlobeNewswire 47 minutes ago.

    0 0

    Clash Albums Of The Year 2018: 10 - 1 And the winner is...

    With streaming services fully taking hold of the music industry in 2018, it’s been an interesting time for the album format. The number of LPs dropping every Friday seems to be increasing, along with the number of tracks per record, while the time we have to consume them decreases.

    Somehow, we've whittled this enormous list down to our 40 personal favourites. The poll has been running all week, and now the time is right to announce the winner...

    - - -

    *10. IDLES - 'Joy As An Act Of Resistance'*If Bristol five-piece IDLES’ debut record ‘Brutalism’ made waves outside of their hometown last year, ‘Joy As An Act Of Resistance’ is its follow-up tsunami. Political but never preachy, sarcastic yet optimistic, full of zeitgeist but chasing any bandwagon, this is the kind of crossover smash that reminds the world at large why punk is still the genre you reach for when you feel like giving the whole world a good kicking.

    It’s easy to just take this music at face value, giggling at Joe Talbot’s ‘plastic Sinatra’ putdowns and grin, like a trained monkey binging on Family Guy reruns, every time you recognise a cultural reference. Engage with their lyrics fully, however, and it becomes clear that there’s far more to IDLES than shouting ‘Fuck the Tories’ and nutting a stranger. “I’m lefty, I’m soft, I’m minimum wage job,” Talbot spits on ‘I’m Scum’, succinctly encapsulating the self-awareness of a record that spends as much time shouting at the mirror as it does raging against the machine.

    Whether it’s toxic masculinity on ‘Samaritans’ or crippling body consciousness on ‘Television’, the underlying message of ‘Joy As An Act Of Resistance’ - that we need to dismantle the prisons that we build ourselves, in order to start piecing our broken society back together - is clear, effective and convincingly argued.

    Though it’s easy to get caught up analysing Talbot’s singular way with words when talking about this album, IDLES are far from a one-man show. Mark Bowen and Lee Kiernan’s high-kicking guitar lines giddily collide, snaking round and round one another before exploding into atomic blasts of distortion. Jon Beavis drums with a controlled ferocity that kicks ‘Never Fight A Man With A Perm’ into another gear, while the beautifully bearded Adam Devonshire crafts the most instantly recognisable bassline of the decade with ‘Danny Nedelko’.

    ‘Joy As An Act Of Resistance’ presents a fully formed, powerful band capable of knitting together fury and joy in a way that never sounds hackneyed or dated.


    - - -

    *9. Various We Out Here *Jazz had a good year in 2018 - there is absolutely no question about that. A seemingly endless treasure trove of material poured out of the London underground over the past 12 months, propelled by a desire to break the rules, to blend different cultures, and create anew.

    With its communal musicality, Brownswood’s ‘We Out Here’ compilation perhaps encapsulated the spirit of London’s jazz scene better than any single release. Overseen by saxophonist and composer Shabaka Hutchings, it was recorded across a series of days at the studio in East London’s Total Refreshment Centre, a hub that has perhaps done for more British jazz than anywhere else in a generation.

    Opening with Maisha’s languid, spiritual ‘Inside The Acorn’, ‘We Out Here’ pulls together all manner of different disciplines and approaches, continually asking questions both of the audience and the musicians therein. Ezra Collective bring the fire on ‘Pure Shade’, and their rabid afro-funk is followed by the rhythmic complexity of ‘The Balance’ by Moses Boyd.

    Fusing club culture, Afrobeat, high life, Afro-Caribbean traditions and more into an unwieldy but inspirational document, ‘We Out Here’ never repeats itself. Theon Cross hails South London on ‘Brockley’, before giving way to Nubya Garcia’s stunning saxophone-led showcase ‘Once’. Hutchings gets in front of the mic on ‘Black Skin, Black Masks’, a complex, challenging work that recalls his own Mercury-nominated work with Sons Of Kemet.

    Triforce steer into the ambient side of fusion’s legacy on ‘Walls’, while Joe-Armon Jones presages his own debut album as a bandleader on the lush, fragrantly melodic ‘Go See’. Kokoroko provide the sunset moment on ‘We Out Here’ with their glacial, endlessly evolving ‘Abusey Junction’, somehow managing to recall Fela Kuti’s more mellow side while remaining firmly rooted in the sights, sounds and smells of London in 2018.

    Indeed, at times ‘We Out Here’ feels like aural cartography, a way of mapping and reinventing a city that often seems like a hostile place to these voices. At time when London can often seem more fragmented, more sterile than ever before, ‘We Out Here’ represented the grass-shoots of community, and the creativity it can engender.


    - - -

    *8. SOPHIE - 'OIL OF EVERY PEARL’S UN-INSIDES' *More than half a decade since the PC Music collective first came into the public consciousness, there are still plenty of unanswered questions; the most pressing of which being: “What are they for?” What seemed initially to be a meditation on popular culture and consumerism masked by multiple layers of irony has, over time, stagnated, to the point where it could now be arguably be seen as artificial as what it sought to critique.

    Adding a second dimension to a movement that wore its single-mindedness as a badge of honour originally seemed misguided at best but, with ‘OIL OF EVERY PEARL’s UN-INSIDES’, SOPHIE broke free of the restrictive nature of the PC Music aesthetic and made the record that takes the group’s art-school pretensions to the next level.

    In fact, those barriers are broken down on the album’s very first song, the naked and affecting, ‘It’s Okay To Cry’. Using her own voice for the first time as a performer, SOPHIE is disarmingly vulnerable, getting straight to the core of an emotional relationship (But with whom? A partner? The world? Herself?) over fluttering synth pads, before rushing to a caffeine-fuelled climax. It’s a rumination on self-identity and the damaging effects of hyper-masculinity, and it’s comfortably the most candid thing SOPHIE has ever committed to record.

    Elsewhere, we’re on slightly more familiar ground. The sleazy, industrial S&M stomp of ‘Ponyboy’ is viscerally thrilling, ‘Immaterial’ is Noughties pop that’s had access to unlimited sugar, and ‘Faceshopping’ creaks, snaps and whistles in all the right places.

    It’s remarkable how SOPHIE makes every element of her tracks percussive, no matter how melodious, and her songs seems purposely designed to provoke a physical reaction. Nowhere is this clearer than on album closer ‘Whole New World / Pretend World’, whose main riff gives the feeling of your inner ears being sandpapered (but, you know, in a good way).

    It all adds up to everything you loved about SOPHIE in the first place, plus a hitherto unseen side that shows the fully rounded artist she’s become.


    - - -

    *7. Pusha T DAYTONA*GOOD Music/Def Jam Leading the charge for Kanye West’s G.O.O.D Music Summer was easily the best of the five albums unearthed from his infamous Wyoming sessions. Pusha T’s ‘DAYTONA’ cut through the bloated rap album formula that we’d become used to: like the luxury watch it takes its name from, the album focuses on pleasing a niche core audience, and impresses the masses as a result.

    From opening track ‘If You Know You Know’, the stage is set for an elitist rap album to be lapped up by those who came up analysing bars and studying liner notes. Before the beat even kicks in, Push has already referenced Pink Floyd, De La Soul, ’N***as In Paris’ producer Hit-Boy and Rich Boy’s 2006 hit ‘Throw Some D’s’, he’s also alluded to past crimes he’s still evading and takes a shot at fraud rappers tripping themselves up with false figures. As Rick Ross puts it on ‘Hard Piano’: “This is for the sneaker hoarders and coke snorters”.

    Hip-hop might have become pop culture, but this album isn’t intended for everyone. It’s difficult to make music feel exclusive when we can access millions of songs from our phones for a £10 subscription. For this generation, streetwear and sneaker drops have replaced the source of excitement that record stores once did, but Pusha manages to bring back that feeling through by trading cultural capital through his lyrics: if you’re in on the punchline then you feel part of the movement, and if not then you’re going to go away and do some digging to brush up on your rap references and cocaine folklore.

    ‘DAYTONA’s prime concerns are time and luxury. The three years it took Pusha to deliver a 21-minute album would be unaffordable to most rappers, who would have to strike while the iron was hot. By staying small, focused and concise here, he makes the biggest statement of his solo career so far - going against the excess and all-you-can-eat approach that’s got the rest of the game caught up is truly a stunt. Pusha T is timeless.


    - - -

    *6. Let’s Eat Grandma - 'I’m All Ears'*Joy is a luxury item. In austerity Britain, real joy - sweet, full-fat pleasure, the kind that still swells the heart and lungs days after its first hit - is to be looked back upon, or anticipated, but never clutched.

    The first time I heard ‘Hot Pink’, my fizzing synapses understood this concept at a chemical level before any rational part of me could vocalise it, and I knew then that nothing tasteful or decorative was going to speak to the human spirit in 2018. It was going to sound like two teenage girls from Norfolk taking a joyride in an already half-smashed up police car. It was divine.

    What I wasn’t prepared for was just how much Let’s Eat Grandma’s second album would marry that hedonism with anxiety, and how badly we needed to hear that emotional crossover reflected in modern pop. “And just when we discovered that we need each other,” they sang, “here our lives keep pulling us away.”

    ‘It’s Not Just Me’ was hair-raisingly good, and that simple sentiment - “I know you’re feeling the same way” - was almost enough by itself. Like great works of magical realism, ‘I’m All Ears’ sways between fantasy and reality, until it’s unclear where the palace ends and the street begins.

    On a record that saw SOPHIE and Faris Badwan contribute to an unlikely production team, it’s also a sonically breathtaking affair. Any attempts at delineation between pop and rock feel more redundant than usual. Sure, the first half of the album shows more of their knack for sugar-rush melodies, with the latter cascading into epic slow-burners, but nothing operates on one track. ‘Ava’ will go down as one of the great ballads of the era, but everything else is a glorious jumble of ideas, constantly seeking out the next level of ballast before soaring off again.

    By the time ‘Donnie Darko’ reels to a close, something has changed. The world feels heavier and lighter all at once, and for all its pain and horror and uncertainty, a connection is forged. Joy prevails.


    - - -

    *5. Robyn - 'Honey'*“No, you’re not gonna get what you need, but baby I have what you need / Come get your honey,” is the hypnotic, charged refrain from the title track ‘Honey’, and the words encapsulate the record’s thorny core. Grief, heartbreak, disenchantment and mundanity tinge the narrative of Robyn’s eighth studio album, but she refuses to succumb to melodrama, instead weaving together a streamlined set of songs that luxuriate in a fervent but meditative ecstasy - the payoff mellower but no less pungent.

    Robyn definitively centres the experience of later-life melancholia through a prism of globetrotting communal club culture. She pays a meta-homage to true dance progenitors but delicately manipulates their sonic archetype for a new audience, like on the samba-staccato hybrid of ‘Beach2k20’, or the Chic-evoking disco heat of ‘Because It’s In The Music’.

    Robyn and her trusted band of collaborators - Metronomy’s Joseph Mount, Klas Åhlund, Adam Bainbridge, Mr. Tophat - cultivate nine tracks that incite movement through sophisticated, subtle distillations in texture and sound. There’s no gimmicky call-and-response and very little in the way of discernible melody, but a softness and deftness in touch that ebbs, flows and trickles like, well, honey. These are synthetic forays that veer from the euphoric high of solitude that has defined Robyn’s musical legacy thus far. Now her come-hither sensuality is matched by an anguished plea for reciprocity.

    Extrapolating pain from pleasure and shirking immediacy, she embraces a reverie of conflict and despondency over fractured electronics, making the auditory experience that much more satiating. Robyn has consistently blurred the parameters of pop music for over two decades, because she’s able to mine truth in emotion and make that paradox of emotion authentic and symphonic.

    ‘Honey’ continues her run of immaculate, minimalist pop confection, managing the tricky feat of making the personal profound whilst also ushering in a new era where creative fulfilment and self-preservation trumps everything else.


    - - -

    *4. Blood Orange - 'Negr**o Swan' *Dev Hynes’ fourth album under the moniker Blood Orange was described by the East London musical polymath as “an exploration into my own and many types of black depression.” To execute this vision in the broadest possible way, he expertly utilises his talent as a producer with a communal approach to music-making.

    Across ‘Negro Swan’s 49 minutes listeners hear from transgender rights activist Janet Mock, Three 6 Mafia co-founder Project Pat, actress Amanda Stenberg and a surprisingly candid Puff Daddy - who asks, “What is it going to take for me to not be afraid to be loved the way, like, I really wanna be loved?” - to name just a few.

    Likewise the musical spectrum is broad; an ambitious collage of pop, R&B, hip-hop and chillwave, and anything else that could be crafted from the equipment that Hynes would find lying around studios in Tokyo, Florence and Copenhagen.

    “The underlying thread through each piece on the album, is the idea of hope,” said Hynes in a statement about the album, “and the lights we can try to turn on within ourselves with a hopefully positive outcome of helping others out of their darkness.” It’s a beautifully sensitive body of work, that arrives in times when it feels increasingly important for us to get to know one another more intimately - not to put differences aside, but to acknowledge and understand our differences so that they can be celebrated.

    By its closing track ‘Smoke’, Hynes basks in self love, declaring “I’m pretty as fuck”, before repeating the mantra “The Sun comes in, my heart fulfils within” as the sublime LP draws its conclusion.


    - - -

    *3. 6LACK - 'East Atlanta Love Letter' *After first making waves in 2016 with his debut project ‘FREE 6LACK’ - a title referring to the contractual hell that he’d been through with his previous label - Atlanta R&B singer 6LACK returned with his highly anticipated sophomore album, ‘East Atlanta Love Letter’.

    If ‘FREE 6LACK’ was an appetiser of what the Peach State native could do musically, then its follow-up was the main course that we’d been waiting for. ‘East Atlanta Love Letter’ draws the listener into a world that’s soundtracked by the city’s trap music, while exposing another side to life in Georgia’s capital; the pain, emotion and tumultuous relationships.

    6LACK lives somewhere in a grey area, wearing his imperfections on his sleeve: juggling his passion for music with his personal life, writing slow jams while finding his own salvation in the city’s club music. “Lately I been listening to trap music / Don’t want to listen if I can’t dab to it,” he sings on ‘Thuggers Interlude’, before admitting: “But I’m a hypocrite, cos here I am with another slow song.” He’s more comfortable being candid on record than in real life, providing therapy for his listeners who can take comfort in his imperfections.

    ‘Unfair’ opens with the lines: “Hope my mistakes don’t make me less of a man / But lately it feel like these shits really can,” and it’s clear that a journey of heartache and pain is set to follow across the next 48 minutes. ‘Let Her Go’ sees 6LACK considering the impact a potential break-up will have on his life, while the down-tempo heart-wrencher ‘Sorry’ finds him regretful as he tries to work his way through a mistake, melodies gliding over a soothing piano loop: “Without you I ain’t shit, but no pressure / Guess I gotta learn my lesson.”

    A self-proclaimed “R&B n***a with a hip-hop core,” 6LACK effortlessly transitions from heart-breaking crooning to braggadocios rapping. He saves the majority of this for the third quarter of the LP, with ‘Balenciaga Challenge’, ‘Scripture’ and ‘Nonchalant’. While the album often feels morose in tone, it does draw a hopeful conclusion. Khalid joins for ‘Seasons’, which announces the arrival of summer in contrast to the cold of the rest of the LP, and the unashamedly romantic closer ‘Stan’ sees 6LACK painting a picture of where he hopes his future will take him.

    ‘East Atlanta Love Letter’ is 6LACK’s statement of intent. It carries on where ‘Free 6LACK’ left off, adding more strings to his already stacked bow. With relatable lyrics about love and heartbreak, he connects so vividly to his fans, who realise that he isn’t so different to them. The impressive selection of guest features - Future, J. Cole, Offset and Khalid - add a little more gloss to what was an already stellar album, and this release cements 6LACK’s status as one of the world’s most exciting and relatable new stars.


    - - -

    *2. Travis Scott - 'Astroworld'*In the days before ‘ASTROWORLD’ was released, a handful of enormous demonic heads appeared in cities across the US. They stood in a monochromatic gold, with dead eyes and a crown of serpentine braids. They landed with mouths agape, forming gateways that invited excited onlookers into the labyrinthine mind of their human likeness - the unmistakable Travis Scott.

    Designed by famed pop-surrealist Dave LaChapelle, the sculptures were undoubtedly more than just a realisation of some aspect of Scott’s grand artistic intent and it is, of course, no coincidence that they happened to be perfectly Instagrammable.

    The 26-year-old Houston native is a zeitgeist-surfing visionary, for whom traditional measures of rap pedigree are incidental. ‘ASTROWORLD’, Scott’s third and most ambitious album to date, makes the case that the man once a student of Kanye West, has perfected his cataclysmic approach to hip-hop that places as much emphasis on curation as it does on creation.

    “It’s like pure imagination, pure liveliness,” Scott said of an in-progress ‘ASTROWORLD’ during our cover interview with him last summer. What finally followed a year later was an expectedly brilliant exercise in escapism and world building. The low-key bounce of the album’s opening, ‘STARGAZING’, only hints at the euphoric heights this wild ride will take us to, first on the Drake-assisted ‘SICKO MODE’, then onwards an upwards to the intensely vibrant Tame Impala cut ‘SKELETONS’, and the already multi- platinum hit, ‘BUTTERFLY EFFECT’.

    The psychedelic fantasia of ‘ASTROWORLD’ is constructed on a foundation of stunning production, out of which both attention-grabbing bangers and surprising oddities are erected. Handpicked contributors and a whole world of disparate influences combine to make something sonically complex and consistently intriguing. Its glittering and varied list of collaborators - from Stevie Wonder, The Weeknd and James Blake to rising rap stars Sheck Wes, Gunna and Juice WRLD - all feel energised by the spectacle they are part of.

    In fact, it is the moments in which Scott and his co-producers expertly weave the performances of featured artists into the project’s idiosyncratic universe that ‘ASTROWORLD’ reaches its most dizzying heights. ‘R.I.P SCREW’ utilises Swae Lee’s angelic vocal to elevate Scott’s heartfelt tribute to Houston rap icon DJ Screw, ‘CAN’T SAY’ introduces the haunting sound of newcomer Don Toliver, and ‘SICKO MODE’ might as well be considered this generation’s ‘Bohemian Rhapsody’.

    In the video for ‘STOP TRYING TO BE GOD’, director Dave Meyers sets up a series of surreal tableaux that attempt to try and visualise the album’s rap-surrealism. Scott baptises followers so that they may receive his holy braids, before ripping through LA on a fire breathing dragon, only to be laser-beamed to death by a God-like man in the sky, also played by Travis.

    Nothing is preposterous, and that is the true genius of the audiovisual landscape cultivated by our protagonist. Imperfect by design, ‘ASTROWORLD’ feels like the first time the otherworldly quality of Travis Scott’s work has been fully realised.

    Whether it’s due to experience, resources or personal influence, this project offers a the kind of playful contrast between his familiar bars and their dystopian backdrop that his previous efforts only ever managed to sustain in short bursts. Just as only the most exciting rollercoasters tease you with the threat of derailment, the pertinent and thrilling sense that ‘ASTROWORLD’ might lose touch of reality altogether is what makes it one of the most inviting, and intriguing, rap albums of recent times.


    - - -

    *1. Christine And The Queens - 'Chris' *Christine And The Queens’ new album ‘Chaleur Humaine’ was daring, distinctive, and entirely original. A remarkable success story, its transition from French to English came just as this country was beginning the process of separating itself from the rest of Europe, a time when - for many - the darker instincts of our psyche were coming to the surface.

    Establishing a potent mythology, Héloïse Letissier was faced with constructing a follow-up more than four years after she first began recording her debut, a time that had changed her body and spirit irrevocably. She had become a new person, it seemed, and that required something new. So Christine became ‘Chris’ and her music became more complex, nuanced, and carnal, while also becoming more focused, more pop fixated, and more immediate than ever before.

    If DaM-FunK-aided lead single ‘Girlfriend’ was the supple, erotically enticing introduction, then what lay ahead was more challenging, and more rewarding than anything she had recorded before. Using touchstones such as Janet Jackson’s incredible erotic opus ‘The Velvet Rope’ as her guide, Chris pulled from drag culture, from ’80s machine funk, and from her own pan-sexual thoughts, dreams, and romances to construct the year’s most vivid, colourful, confusing, and addictive pop full-length.

    ‘Doesn’t Matter’ revolves around those distorted Cameo-esque drum machine kicks as Chris grapples with magic, with sex, with the unknowable powers that pulse through our everyday experiences. “If I could just push this door chalked on the wall,” she sings at one point, “if after the void there's somewhere else to fall.”

    Everything about ‘Chris’ revolves around extremes. From lust to anger, pain and regret, each emotion is pushed out to its furthest reaches, with its central figure distorted, emboldened, and empowered after four years of touring; her voice broader, her body hardened, her conception of ‘Chris’ informed by adoring crowds, and the rush of audiences.

    The thrill of performance seems to underpin ‘5 Dollars’, one of the album’s boldest moments, one of its most stirring arrangements, and starkest vocals. “You’re eager and unashamed,” she sings, before adding: “I grieve by dying every night, baby…”

    But there’s still an inherent eroticism in this cry, and it’s something communicated through almost every single line on ‘Chris’. ‘Feel So Good’ is exuberant, carefree with its cry of “just one fling,” while ‘Damn (What Must A Woman Do)’ couples its proto-house, jackin’ electro feel to that seductive line: “Naked with opened door / Encore, encore…”

    That isn’t to suggest, though, that Chris has out-run her insecurities, that success has stained her melancholies - they still surface, and often erupt in the most unexpected, and most violent of manners. ‘The Walker’ addresses this explicitly, her own doubts, fears, self-loathing erupting as a vision of the aftermath of brutality, her body damaged but unbowed. Bruises are reimagined as flowers, with Chris again returning to drag culture, to the concept of ownership, and the ability to recontextualise your physical faults as something divine, or grotesque, but always beautiful.

    And ultimately, ‘Chris’ is a terrifically beautiful record. A phenomenal technical achievement, it’s imbued by a sense of accuracy and precision, with Christine And The Queens being forever driven by an impassioned lust towards new ideas, and fresh aesthetics.

    It’s bold but also subtle; it’s a complex puzzle, but also incredibly immediate. It’s another mutation from one of our generation’s most distinctive pop auteurs. It’s Chris.


    - - -

    Miss Part One? Try *HERE.*

    Miss Part Two? Try *HERE.*


    Join us on *Vero*, as we get under the skin of global cultural happenings. Follow *Clash Magazine* as we skip merrily between clubs, concerts, interviews and photo shoots. Get backstage sneak peeks and a true view into our world as the fun and games unfold.

    ***B*uy Clash Magazine** Reported by Clash 21 minutes ago.

    0 0

    According to the report, the global methyl methacrylate (MMA) adhesives market was valued at USD 1.01 billion in 2017 and is expected to reach USD 1.68 billion by 2024, growing at a CAGR of 7.5% between 2018 and 2024.

    New York, NY, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled *“Methyl Methacrylate (MMA) Adhesives Market by Substrate (Metal, Plastic, Composite, and Others) and by End-Use (Automotive & Transportation, Building & Construction, Marine, Wind Energy, General Assembly, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017—2024”*. According to the report, the global methyl methacrylate (MMA) adhesives market was valued at USD 1.01 billion in 2017 and is expected to reach USD 1.68 billion by 2024, growing at a CAGR of 7.5% between 2018 and 2024.

    Methyl methacrylate (MMA) adhesives are fundamental adhesives developed to bond metals, plastics, and composites. MMA adhesives are tough, flexible, and easy to use.

    *Browse through 92 Tables & 30 Figures spread over 110 Pages and in-depth TOC on “Global Methyl Methacrylate (MMA) Adhesives Market: Industry Type, Size, Share, Demand, Applications, Analysis and Forecast, 2017—2024”.*

    *Request Free Sample Report of Global Methyl Methacrylate (MMA) Adhesives Market Report @*

    The automotive and transportation is the fastest growing end-user of the methyl methacrylate (MMA) adhesives market. The increased use of methyl methacrylate (MMA) adhesives in automotives is expected to witness a significant rise over the forecast time period. However, the volatile raw material costs might hamper this market. Nevertheless, the growing popularity of eco-friendly, non-toxic, and sustainable adhesives are likely to create new growth opportunities for the major players operating in the methyl methacrylate (MMA) adhesives market on a global scale.

    Based on the substrate, the global methyl methacrylate (MMA) adhesives market is divided into metal, plastic, composite, and others. In 2017, composites dominated the market and held a significant share. Composites are most preferable MMA due to their use in varied connecting composite items, such as bumpers, deflectors, composite tanks, roofs, car seats, blades, instrument panels, and interior body panel structures of cars, trucks, buses, tanks, and rails. Based on end-use, this global market is mainly segmented into automotive and transportation, building and construction, marine, wind energy, general assembly, and others. In 2017, the automotive and transportation industry dominated the MMA market. Methyl methacrylate (MMA) adhesives offer excellent performance along with reducing vehicle weight. These adhesives applications have revolutionized the building and design processes in the automotive industry. The rising product demand in automotive and transportation, building and construction, marine, and wind energy, particularly in the BRICS (Brazil, Russia, India, China, and South Africa) nations, is projected to drive the methyl methacrylate (MMA) adhesives market in the next few years. The marine sector uses methyl methacrylate (MMA) adhesives due to their excellent gap filling ability, reduced gel coat cracking, and superior performance for laminated joints.

    *Download Free Report PDF Brochure: *

    In 2017, Asia Pacific was the largest share for the methyl methacrylate (MMA) adhesives market. In terms of value, Asia Pacific is estimated to grow at the highest rate of growth in the future. This regional growth can be primarily attributed to the rising product demand in various end-use industries. In addition, this region’s trade and commerce activities are growing continuously. China and India are the region’s major markets for methyl methacrylate (MMA) adhesives. In European and North American markets, because of economic contraction and saturation, the demand for methyl methacrylate (MMA) adhesives is shifting toward Asia Pacific. With increased domestic demand and easy access to required resources, Asia Pacific is anticipated to emerge as one of the leading producers and consumers in the methyl methacrylate (MMA) adhesives (MMA) adhesives market.

    North America was the second largest methyl methacrylate (MMA) adhesives market in 2017 globally. This was due to the growing industrial activities due to the increased use of methyl methacrylate (MMA) adhesives in automotive and transportation, marine, and wind energy sectors. The North American methyl methacrylate (MMA) adhesives market is likely to be driven by flourishing automotive and food packaging sectors and the rising industrial activities in the U.S. and Canada in the forecast time period.

    Browse the full *"Methyl Methacrylate (MMA) Adhesives Market by Substrate (Metal, Plastic, Composite, and Others) and by End-Use (Automotive & Transportation, Building & Construction, Marine, Wind Energy, General Assembly, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017—2024"* Report At

    Europe is expected to witness sustainable growth in the methyl methacrylate (MMA) adhesives market in the future. Spending in construction and infrastructural sectors, especially in UK, Germany, and France, is expected to propel this market over the estimated time period. In Europe, the flourishing automotive sector and increasing consumer disposable income are projected to further fuel the methyl methacrylate (MMA) adhesives in the future.

    The Latin American and the Middle Eastern and African markets are projected to witness massive growth over the forecast time period, owing to the huge investments made by the international players in methyl methacrylate (MMA) adhesives projects in both these regions. These activities are likely to help the methyl methacrylate (MMA) adhesives market gain traction in the future. Improving economic activities are further expected to boost the regions’ methyl methacrylate (MMA) adhesives market in the upcoming years.

    *Inquire more about this report before purchase @ *

    The major vendors of the global methyl methacrylate (MMA) adhesives market include The 3M Company, Arkema, Illinois Tool Works Inc., Lord Corporation, Scott Bader, SCIGRIP, Henkel AG & Company, Lord Corporation, Parsons Adhesives, Inc., Permabond LLC, and Huntsman Corporation, among others.

    *Request customized copy of report @ *

    *This report segments the global methyl methacrylate (MMA) adhesives market into:*

    *Global Methyl Methacrylate (MMA) Adhesives Market: Substrate Analysis*

    · Metal
    · Plastic
    · Composite
    · Others

    *Global Methyl Methacrylate (MMA) Adhesives Market: End-Use Analysis*

    · Automotive and Transportation
    · Building and Construction
    · Marine
    · Wind Energy
    · General Assembly
    · Others

    *Global Methyl Methacrylate (MMA) Adhesives Market: Regional Analysis*

    · North America

    · The U.S.

    · Europe

    · UK
    · France
    · Germany

    · Asia Pacific

    · China
    · Japan
    · India

    · Latin America

    · Brazil

    · The Middle East and Africa

    *Related Reports:*

    · *Cross Laminated Timber (CLT) Market: *
    · *Extruded Polypropylene (XPP) Foam Market: *
    · *Bioethanol Market: *
    · *Bio Plasticizers Market:*
    · *Fatty Alcohol Market: *                                            

    *About Us:*

    Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

    *Follow Us LinkedIn: *
    *Follow Us Twitter: *

    *Blog:* |

    *Contact Us:*

    Joel John
    244 Fifth Avenue, Suite N202
    New York, 10001, United States
    Tel: +49-322 210 92714
    USA/Canada Toll-Free No.1-855-465-4651


    * Blog:* Reported by GlobeNewswire 28 minutes ago.

    0 0

    Tel Aviv, Israel, Dec. 19, 2018 (GLOBE NEWSWIRE) -- *Elbit Imaging Ltd. (TASE, NASDAQ: EMITF)* ("*Elbit*" or the "*Company*") announced today that Insightec Ltd. ("*Insightec*") informed that the  Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has approved an expansion of the indication of Exablate Neuro to include the treatment of patients with tremor-dominant Parkinson’s disease ("*PD*"). This expansion adds medication-refractory tremor from PD to the current Exablate Neuro indication for incisionless, focused ultrasound thalamotomy for medication-refractory essential tremor.

    The Company holds approximately 63% of the share capital of Elbit Medical Technologies Ltd. (TASE: EMTC-M) (approximately 41% on a fully diluted basis) which, in turn, holds approximately 22% of the share capital in Insightec (approximately 18.5% on a fully diluted basis).** **

    *About Elbit Imaging Ltd.*

    Elbit Imaging Ltd. operates in the following principal fields of business: (i) Medical Industries through our indirect holdings in Insightec Ltd. and Gamida Cell Ltd.; (ii) Plots in India which are designated for sale (and which were initially designated for residential projects); (iii) Plots in Eastern Europe which are designated for sale (and which were initially designated for development of commercial centers).

    *For Further Information:*
    *Company Contact*
    *Ron Hadassi*
    CEO and Chairman of the Board of Directors
    Tel: +972-3-608-6048
    Fax: +972-3-608-6050 Reported by GlobeNewswire 28 minutes ago.

    0 0

    Two female founders of Emotion Labs, graduates of US Top-5 "Alchemist" startup accelerator, launch the first stress and emotion monitoring gamified smartwatch

    SAN FRANCISCO (PRWEB) December 19, 2018

    Emotion Labs, a highly-acclaimed tech startup, introduces EMwatch, a breakthrough in preventive health and emotional monitoring technology, for the first time available in the form of a gamified smartwatch.

    Just last year, national stress levels were reported at an all time high due to economic, social, political tensions. EMwatch has made it its mission to fully reshape daily stress management practices and is able to predict 75% of stress-related diseases thanks to more than three years of research by a team of a dozen biological and technological  scientists.

    Going beyond the rudimentary time keeping and notes functions of early generation smartwatches, EMwatch is the first smart gadget to calculate your stress and stamina levels in real time, and by using AI algorithms, the EMwatch App will recommend how to reduce stress and will monitor customer’s progress along the way.  The users will also benefit from one of the longest lasting batteries in the industry - up to 14 days. 
    The cutting-edge, stress monitoring technology earned its female founders a spot in "The Alchemist", which is ranked among top-5 US Tech accelerators for the most promising startups.  It is one of the few hardware startups to break even so fast, as initial launch of the product sold out in less than 2 weeks in Europe.
    The EMwatch team is excited to bring this innovative product to the US market with a launch at Consumer Electronics Show in Las Vegas in January 2019.

    "Our emotional monitoring avatar, a polar bear, responds to biological measurements with digitally animated feedback to inform users of their real-time stress levels. Before we’ve even entered the US market, several Fortune 500 companies have already expressed interest in incorporating EMwatch as part of their employee wellness programs,” says Lisa Voronkova, one of the smartwatch startup's founders.

    Come experience the ground-breaking wellness technology in Booth# 53351, Eureka Park at CES Las Vegas on January 8-11th. Get your EMwatch at a promotional launch price of $129 on Amazon.

    180 Sansome Street, San Francisco CA 94104 Reported by PRWeb 19 minutes ago.

    0 0

    Among Vehicles at Various Price Points below $65,000, 18 of 20 Top Scores Belong to Sedans

    COSTA MESA, Calif. (PRWEB) December 19, 2018

    Model-year closeouts and manufacturer incentives are two reasons why car shopping experts affirm that fall is the best time of year to purchase a new or used vehicle. With the New Year looming, today announced the highest-rated 2018 models at price points below $65,000, with sedans accounting for 18 of the top 20 vehicles in terms of overall ownership satisfaction.

    “When it comes time to choosing one’s next vehicle, is the ultimate resource for actual, verified car-ownership experiences,” said Troy Snyder, Vice President, Consumer Division at J.D. Power. “Whether shopping for vehicles in the same segment or deciding if it’s worth springing for a more premium model, shoppers who use our new Compare Cars tool can make a wiser purchase decision.”

    The Compare Cars tool allows users to match three different models to simultaneously evaluate 100-point overall scores as well as other metrics including quality, dependability, performance and depreciation. To make research user-friendly, selected models remain saved within a digital tray as visitors browse from one page to another.

    “While consumer interest continues to shift towards crossovers, many cars are still proving extremely satisfying to own,” said Dave Sargent, Vice President, Global Automotive at J.D. Power. “The very best cars often score better for quality and appeal than crossovers at the same price point. We also see that more expensive vehicles score better, which is not surprising. These vehicles tend to be larger, more comfortable, more powerful, have better interiors and have more of the features that today’s consumers crave.”

    The four categories, based on price points, in the comparison are:

    Top Vehicles $15,000-$19,999

    1. 2018 Kia Soul (79 points out of 100)
    2. 2018 Kia Rio (79)
    3. 2018 Hyundai Elantra (77)
    4. 2018 Kia Forte (76)
    5. 2018 Chevrolet Sonic (75)

    Top Vehicles $20,000-$32,999

    1. 2018 MINI Countryman (83)
    2. 2018 Toyota Corolla (83)
    3. 2018 Nissan Altima (83)
    4. 2018 Chevrolet Impala (83)
    5. 2018 Chevrolet Cruz (82)

    Top Vehicles $33,000-$44,999

    1. 2018 Infiniti Q60 (87)
    2. 2018 Lincoln MKC (87)
    3. 2018 Lexus ES (87)
    4. 2018 Lexus IS (87)
    5. 2018 Audi A5 Coupe (86)

    Top Vehicles $45,000-$65,000

    1. 2018 Lincoln Continental (92)
    2. 2018 Lexus RX (91)
    3. 2018 Lexus GS (90)
    4. 2018 Genesis G80 (90)
    5. 2018 Mercedes-Benz GLC (89)

    The site’s data is sourced from more than 3.2 million verified ownership experiences from J.D. Power studies. To compare vehicle ratings, rankings, reviews and awards, visit

    J.D. Power is a global leader in consumer insights, advisory services and data and analytics. These capabilities enable J.D. Power to help its clients drive customer satisfaction, growth and profitability. Established in 1968, J.D. Power is headquartered in Costa Mesa, Calif., and has offices serving North/South America, Asia Pacific and Europe. J.D. Power is a portfolio company of XIO Group, a global alternative investments firm headquartered in London, and is led by its four founders: Athene Li, Joseph Pacini, Murphy Qiao and Carsten Geyer.

    Media Relations Contacts
    Geno Effler; J.D. Power; 714-621-6224;
    Shane Smith; East Coast; 424-903-3665;

    About J.D. Power and Advertising/Promotional Rules Reported by PRWeb 23 minutes ago.

    0 0

    GlobalSign SSL/TLS certificates are being offered by Safescrypt, the data security business of Sify across India and other SAARC countries

    Santa Clara, California, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Sify Technologies Limited (NASDAQ: SIFY), headquartered at Chennai, India, an ICT Solutions and Services leader in India, today announced a partnership with GMO GlobalSign, a leading provider of trusted identity and security solutions and one of the longest established Certificate Authorities in the world to offer SSL/ TLS Certificates to customers across India and other SAARC countries. This partnership makes Safescrypt, the data security solution arm of Sify, one of the largest Channel Partners for GMO GlobalSign in the region.

    The partnership would expand the geographical reach for both organizations and importantly, make SSL Certificates more accessible to customers from across industries in the region. It would also ensure quick and hassle-free certificate installations.

    In the wake of recent developments in online security, when Google Chrome started labelling non-HTTPS sites as “Not Secure”, SSL Certificates have become essential for businesses of all sizes. As a trusted Certificate Authority, GMO GlobalSign is uniquely positioned to offer reliable solutions to organizations looking to secure their online presence.

    SSL Certificates from GlobalSign allows trusted, secure and encrypted information exchange between browsers and webservers, websites and networks. GlobalSign's fully automated and scalable, managed PKI solution helps organizations manage enterprise-wide certificates. With over 60 million digital certificates/identities issued to people, servers and devices, the Japan-based Certificate Authority has built an enviable reputation globally.

    "We are excited about this partnership. As the world moves towards a secure web, GMO GlobalSign, as a trusted CA, has a larger role to play in the security ecosystem of the region. This partnership would provide further impetus to our consistently growing market share", said *Aditya Anand*, General Manager, India, SAARC & Middle East, GMO GlobalSign.

    *Debanjan Kumar*, Business Head–AIS, Sify, said, “As security certification becomes generic to business environments, the need of the hour is credibility, reach and turnaround time. Sify chose to partner with GMO GlobalSign given their reputation in the Digital Certification market globally. In extending this service to the SAARC markets, both Sify and GlobalSign are seeking to explore a hitherto nascent market.”*About Sify Technologies:*
    Sify is the largest ICT service provider, systems integrator, and all-in-one network solutions company on the Indian subcontinent. We’ve also expanded to the United States, with headquarters in the heart of California’s Silicon Valley.

    Over 10000 businesses have become Sify customers. We also partner with other major network operators to deliver global network solutions. Our customers can access Sify services via India’s largest MPLS network. Among the very few Enterprise class player in India, Sify, today has presence in more than 1600 cities in India and in North America, the United Kingdom and Singapore.

    Sify,, Sify Technologies and are registered trademarks of Sify Technologies Limited. Discover how we can help guide your organisation in these times of ‘Digital’ here.

    *About GMO GlobalSign:*
    GlobalSign is the leading provider of trusted identity and security solutions enabling businesses, large enterprises, cloud-based service providers and IoT innovators around the world to conduct secure online communications, manage millions of verified digital identities and automate authentication and encryption. Its high-scale PKI and identity solutions support the billions of services, devices, people and things comprising the Internet of Everything (IoE). The company has offices in the Americas, Europe and Asia. For more information, visit 

    For further information, please contact:

    CONTACT: Praveen Krishna
    Sify Technologies Limited
    +91 9840926523

    Latika Raman
    GMO GlobalSign Certificate Services Private Ltd.
    +91 11 4110 6033

    Nikhila Kesavan
    20:20 Media
    +91 9840124036

    Shiwei Yin
    Grayling Investor Relations
    +1-646-284-9474 Reported by GlobeNewswire 18 minutes ago.

    0 0

    CINCINNATI, OH, Dec. 19, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- *Callitas Health Inc.** *(CSE: LILY, OTCBB: MPHMF, FWB: T3F3), today announced that President and Chief Executive Officer, James Thompson, has issued the following letter to shareholders.Dear Shareholders:

    We would like to thank you for your continuing commitment as we strive to build Callitas Health into a strong player in the health, wellness and cannabis pharmaceutical delivery industry. We started 2018 with ambitious goals and ended the year overcoming many challenges, achieving many accomplishments, all while setting the stage for a stronger, successful 2019 and future.

    With the close of fiscal year 2018, and acknowledging the overall decline in the stock value, we wanted to provide some insight to shareholders including: some challenges that occurred in 2018, summarize some key achievements, and detail what we anticipate for 2019. Our foremost priority is creating significant shareholder value, over time, through new IP development/in-licensing, new product R&D, sales, marketing and licensing. Some of these operations, which cannot be disclosed until finalized, take significant time to realize revenues without creating a competitive disadvantage to ourselves (or partners) or violating non-disclosure agreements. In 2018, we set the stage for significant revenue growth by quickly advancing partnerships and sales operations, while adding new products, continuing R&D and licensing our technology, which will begin in early 2019. Additionally, in 2018, we spent a considerable amount of time and resources improving and enhancing our Over-The-Counter (“OTC”) product pipeline, our CannaPharma delivery technologies portfolio, and advancing our pipeline of drug candidates, while adding new business partners and increasing our overall visibility with the financial community.

    *2018 Challenges*

    · In January 2018, we announced that Gary Thompson was temporarily stepping down as President & CEO due to ongoing health issues. Unfortunately for the entire Callitas family, Gary passed in mid-September after a valent struggle against brain cancer. His loss is still felt by employees and our partners.
    · In late August 2018, Erin Thompson, wife of James Thompson, President & CEO, suffered a ruptured aneurism and massive hemorrhagic stroke while exercising; she survived, spent two plus months in Neurosurgery ICU and is now recovering in a Skilled Nursing/Stroke Rehab Center in Cincinnati, OH. This devastating event, paired with the hospice stay and passing of Gary Thompson mid-September, were dual contributing factors to the delay in filings mentioned below, and the advancement/closing of some business development milestones on the OTC and cannabis businesses. 
    · In early September 2018, the Company was notified by the British Columbia Securities Commission of regulatory deficiencies for failure to file second quarter 2018 financial statements and management discussion and analysis prior to the August 30, 2018 deadline. This deficiency was cured early October and the shares resumed trading October 19, 2018. The trading halt negatively impacted the company perception in the short run and delayed some operations and capital raising discussions. The delay in the Q2 filing were due specifically to the aforementioned personal tragedies. 

    *Pipeline & Partnering Progress * 

    *OTC Health & Wellness-*

    ·      October 2017: We successfully launched* *ToConceive, our proprietary FDA cleared fertility enhancement product via a multi-channel direct-to-consumer strategy. (*ToConceive *is a vaginal gel, lubricant and moisturizer, clinically shown to help increase a woman’s own natural conception lubrication, called transudate, which helps aid in conception). As we continue to expand ToConceive’s presence in the U.S. we are evaluating additional retail opportunities and investigating global expansion.

    ·      February 2018: We began a partnership and co-branding opportunity for our ToConceive fertility lubricant with NFI Consumer Healthcare’s e.p.t®, the OTC pregnancy test kit brand that includes promotional opportunities on shelf, product samples and new product inclusion at major food, drug and mass retailers throughout the United States. This partnership should begin generating revenue from US retail marketing in early 2019 and provide a fertility channel retail partner for additional products in our pipeline.

    ·      We have renewed our partnership with Lifestyles® for the licensing of our female enhancement gel brand Excite by SKYN. We commenced product development for Lifestyles on a new item for 2019 which, should be released to major U.S. food, drug and mass retailers.   

    ·      Callitas is evaluating International Expansion of OTC products in direct sales, MLM, online and retail in select international markets; specifically targeting Canada, Europe, India, Asia, Latin America, where we have begun discussions with local consultants to advance these sales initiatives.

    ·      Callitas has begun and advanced new products R&D for the following products to support our OTC partners pipelines in the US and international:

    --   Fertility oral supplement

    --   Prenatal oral vitamins

    --   Weight loss/metabolism oral supplement

    --   Female enhancement oral supplement

    --   Male enhancement gels

    ·      Callitas is evaluating new business acquisitions and licensing of additional products and assets for the US markets, specifically a medical foods company targeting bariatric patients, older adults and obese individuals.

    *CannaPharma Delivery Technologies*

    We continue to see momentum and significant revenue potential in developing for our Cannabis Pharmaceutical (CannaPharma) Delivery Technologies through partnering with local, regional, national and international partners. As the CannaPharma industry rapidly expanded, we entered the market and have quickly achieved several milestones. We have co-developed or in-licensed the following IP and technologies in the Cannabis (THC and/or CBD) delivery field:

    ·      Novel Oral THC/CBD strip delivery technology, developed to enhance oral/mucosal delivery of THC/CBD. 

    ·      Novel Topical Formulations for CBD/THC delivery (Sexual Wellness, Pain Management & Skincare)

    ·      Biphasic Release Candy Tech

    ·      Sustained Release Oral Delivery Tech

    ·      Business Methods IP & Proprietary Equipment for precise dosing

    ·      Novel Vapor & Decarboxylation Tech

    ·      Novel Patch Delivery Tech

    We are excited about our recent partnering discussions and hope to be able to share additional updates on this critical sector of our overall business.

    *Rx Development*

    ·      Callitas temporarily paused the Rx development projects in August 2018 due to the personal challenges mentioned above. However, we have restarted these programs and are currently evaluating partners for C-103, Extrinsa and Orphan Drug. In early 2018, we:

    --   Continued our* *Phase II study on C-103, our reformulated version of orlistat for weight loss. 

    --   Began our preliminary Phase II work on Extrinsa™, a reformulated topical tadalafil for female sexual dysfunction.

    --   Advanced our Orphan Drug product development, through submission of an Orphan Drug Designation and Rare Pediatric Disease Designation(s).  We received feedback from the FDA, will perform some planned, requested testing, and resubmit our application to the FDA.  Product manufacturing is underway and should be available for required studies in Q1 2019.

    *Management and Advisory Board Enhancement * 

    · In January 2018, we announced that Gary Thompson was temporarily stepping down as President & CEO due to ongoing health issues (ultimately a brain tumor that took his life in September) and that the Board appointed me as Interim President & Chief Executive Officer. Subsequently, I was promoted to President & CEO when Gary retired in June. The focus of the management team remains unchanged; to accelerate the numerous initiatives already underway, as well as, developing new partnerships, products and opportunities that will enhance overall shareholder value. With new initiatives in the cannabis space accelerating and the OTC business expanding, we will look to add additional members to our team to further advance our products, marketing, sales, and additional partners.
    · Following my appointment, we were delighted to announce that* *Dr. Laura Berman was appointed to the role of Chief Health Advisor. Dr. Berman is a world-renowned sex and relationship educator, researcher and therapist, as well as TV, radio and internet host, and a New York Times best-selling author on sexual health and pleasure. Dr. Berman also acts as assistant clinical professor of OBGYN and psychiatry at the Feinberg School of Medicine at Northwestern University in Chicago. Dr. Berman is assisting us with the promotion ToConceive and providing insight and consultation on the development of other products.
    · In the summer, we added Dr. Gregory Smith as our Chief Cannabis Advisor. Dr. Smith earned his medical degree from Rush Medical School in Chicago, and a Masters of Public Health from Harvard University. He completed residency training in Preventive Medicine at Walter Reed Army Medical Center. Since getting out of the US Army as a Major, Dr. Smith has been in primary care practice in California, Georgia and Florida for the past 30 years. He first trained on use of medical cannabis in California in 2000. He has had extensive experience and education in the field of cannabinoid medications.  Dr. Smith is an avid writer, having published over a dozen peer reviewed medical publications, two medical textbooks, and a novel called "Malpractice.” His most recent textbook, is entitled *Medical Cannabis: Basic Science and Clinical Applications* (Aylesbury Press, 2016 – It is a scientifically-based textbook directed at educating medical students and medical professionals on the science and applications of cannabinoid medications. His recently released book for patients and caregivers is called *CBD: What You Need to Know* (Kindle Press, 2017). Dr. Smith has been working with medical cannabis-related issues full-time for the past 4 years. He is a prolific writer on the topic of clinical applications of medical cannabis with many publications and video training courses. He is editor-in-chief of, and Director of Medical Affairs for First Harvest Financial, Inc. (a cannabis investment firm.)

    *Increasing our Profile with the Investor Community*

    Throughout 2018, we continued our efforts to increase the Company’s visibility with the investor community. We engaged in numerous meetings with members of the financial community and our management team attended, participated and presented at several key scientific and investor events.

    *Going Forward* 

    We expect 2019 to be a breakout year. Management will focus on creating shareholder value through progress on our clinical and pre-clinical milestones, executing on partnership opportunities, expanding our OTC presence, and quickly capitalizing on the Cannabis opportunities in the U.S. and abroad, in both CBD and THC legal markets. We will continue to make our shareholders our top priority as we achieve a series of key milestones in 2019. Callitas Health is well positioned for growth and the Management team plans to fully execute our focus business strategy in the New Year.   


    James Thompson
    President and Chief Executive Officer

    *About Callitas Health*

    Formed in early 2015, Callitas Health Inc. is an integrated clinical-stage pharmaceutical development and OTC consumer goods marketing company, focused on developing innovative technologies for weight management, female sexual health and wellness, cannabis delivery technologies and other proprietary drugs. In addition to its recent acquisitions of C-103, a reformulation of Orlistat, Extrinsa and assets from 40J’s LLC, the Company successfully launched ToConceive in North America as a clinically proven option for couples struggling with the inability to conceive (, and is in the research and development and business development process for its other OTC products, cannabis dosing technologies and orphan drug technologies. For more information visit

    Callitas Health Inc. trades on the Canadian Securities Exchange (CSE) under the ticker symbol “LILY” as well as on the OTCQB as “MPHMF” and FWB (Frankfurt Stock Exchange) as “T3F3.”

    For more information contact:
    Callitas Investor Relations
    Phone: +1 (859) 868-3131

    *Notice regarding Forward Looking Statements:** *This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval and the commercialization of the rights to the Company’s biomedical & drug technologies.  Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on and the Company’s filings to the CSE at  Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

    *Notice regarding investigational devices:*  C-103 and Extrinsa are investigational drugs or devices and are not currently available outside of approved clinical trials.  Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.   Reported by GlobeNewswire 18 minutes ago.

    0 0



    Person subject to the notification requirement
    Position: Member of the Board/Deputy member

    Issuer: Evli Bank Plc
    LEI: 743700VK1NB8HRGTQH74

    Notification type: INITIAL NOTIFICATION
    Reference number: 743700VK1NB8HRGTQH74_20181219141717_6


    Transaction date: 2018-12-17
    Instrument type: SHARE
    ISIN: FI4000170915
    Nature of the transaction: ACQUISITION

    Transaction Details
    (1): Volume: 100 Unit price: 8.1 EUR
    (2): Volume: 180 Unit price: 8.1 EUR
    (3): Volume: 98 Unit price: 8.1 EUR
    (4): Volume: 1 154 Unit price: 8.04 EUR
    (5): Volume: 57 Unit price: 8.04 EUR
    (6): Volume: 89 Unit price: 8.02 EUR
    (7): Volume: 100 Unit price: 8.02 EUR
    (8): Volume: 150 Unit price: 8.02 EUR
    (9): Volume: 2 500 Unit price: 8.1 EUR
    (10): Volume: 55 Unit price: 8.1 EUR
    (11): Volume: 55 Unit price: 8.1 EUR
    (12): Volume: 55 Unit price: 8.1 EUR
    (13): Volume: 55 Unit price: 8.1 EUR
    (14): Volume: 43 Unit price: 8.1 EUR
    (15): Volume: 12 Unit price: 8.1 EUR
    (16): Volume: 55 Unit price: 8.1 EUR
    (17): Volume: 55 Unit price: 8.1 EUR
    (18): Volume: 37 Unit price: 8.1 EUR
    (19): Volume: 50 Unit price: 8.1 EUR
    (20): Volume: 50 Unit price: 8.1 EUR
    (21): Volume: 5 Unit price: 8.1 EUR
    (22): Volume: 55 Unit price: 8.1 EUR
    (23): Volume: 55 Unit price: 8.1 EUR
    (24): Volume: 55 Unit price: 8.1 EUR
    (25): Volume: 18 Unit price: 8.1 EUR

    Aggregated transactions
     (25): Volume: 5 138 Volume weighted average price: 8.08058 EUR


    Transaction date: 2018-12-17
    Instrument type: SHARE
    ISIN: FI4000170915
    Nature of the transaction: ACQUISITION

    Transaction Details
     (1): Volume: 45 Unit price: 8.1 EUR
    (2): Volume: 12 Unit price: 8.1 EUR
    (3): Volume: 7 Unit price: 8.1 EUR
    (4): Volume: 45 Unit price: 8.1 EUR
    (5): Volume: 45 Unit price: 8.1 EUR
    (6): Volume: 45 Unit price: 8.1 EUR
    (7): Volume: 7 Unit price: 8.1 EUR
    (8): Volume: 13 Unit price: 8.1 EUR
    (9): Volume: 13 Unit price: 8.1 EUR
    (10): Volume: 45 Unit price: 8.1 EUR
    (11): Volume: 72 Unit price: 8.08 EUR
    (12): Volume: 13 Unit price: 8.1 EUR

    Aggregated transactions
     (12): Volume: 362 Volume weighted average price: 8.09602 EUR


    Transaction date: 2018-12-18
    Instrument type: SHARE
    ISIN: FI4000170915
    Nature of the transaction: ACQUISITION

    Transaction Details
    (1): Volume: 250 Unit price: 8 EUR
    (2): Volume: 799 Unit price: 8 EUR
    (3): Volume: 50 Unit price: 8 EUR
    (4): Volume: 150 Unit price: 8 EUR
    (5): Volume: 200 Unit price: 8 EUR
    (6): Volume: 805 Unit price: 8 EUR
    (7): Volume: 180 Unit price: 8 EUR
    (8): Volume: 196 Unit price: 7.98 EUR
    (9): Volume: 15 766 Unit price: 8.05 EUR

    Aggregated transactions
    (9): Volume: 18 396 Volume weighted average price: 8.04264 EUR

    Transaction date: 2018-12-18
    Instrument type: SHARE
    ISIN: FI4000170915
    Nature of the transaction: ACQUISITION

    Transaction Details
    (1): Volume: 59 Unit price: 7.98 EUR

    Aggregated transactions
    (1): Volume: 59 Volume weighted average price: 7.98 EUR


    Transaction date: 2018-12-18
    Instrument type: SHARE
    ISIN: FI4000170915
    Nature of the transaction: ACQUISITION

    Transaction Details
     (1): Volume: 45 Unit price: 7.98 EUR

    Aggregated transactions
     (1): Volume: 45 Volume weighted average price: 7.98 EUR

    Transaction date: 2018-12-19
    Instrument type: SHARE
    ISIN: FI4000170915
    Nature of the transaction: ACQUISITION

    Transaction Details
     (1): Volume: 570 Unit price: 7.9 EUR

    Aggregated transactions
     (1): Volume: 570 Volume weighted average price: 7.9 EUR


    *For additional information, please contact:
    *Mikaela Herrala, IR-Manager, Evli Bank Plc, tel. +358 50 544 5740,

    *Evli Bank Plc*

    Evli is a bank specialized in investments that helps institutions, corporations and private persons increase their wealth. The product and service offering includes mutual funds, asset management and capital markets services, alternative investment products, investment research, administration of incentive programs and Corporate Finance services. The company also offers banking services that support clients' investment operations. Evli is the highest ranked and most used institutional asset manager in Finland*.

    Evli has a total of EUR 12.3 billion in client assets under management (net 9/2018). The Evli Group's equity capital totals EUR 74.3 million and its BIS capital adequacy ratio is 15.3 percent (September 30, 2018). The company has more than 250 employees. Evli Bank Plc's B shares are listed on Nasdaq Helsinki Ltd.

    *KANTAR SIFO Prospera External Asset Management Finland 2015, 2016, 2017, 2018, SFR Scandinavian Financial Research Institutional Investment Services, Finland 2015, 2016, 2017, 2018.

    *Distribution:* Nasdaq Helsinki Ltd, main media, Reported by GlobeNewswire 18 minutes ago.

    0 0

    Europe’s upcoming CO2 standards for trucks will be the first of their kind. Policymakers need to build enough flexibility into the legislation so that manufacturers can adapt as the process and technologies evolve, writes Joachim Drees. Reported by EurActiv 18 minutes ago.

    0 0

    Dublin, Dec. 19, 2018 (GLOBE NEWSWIRE) -- The "Artificial Grass Market - Forecasts From 2018 to 2023" report has been added to *'s* offering.

    The Artificial grass market is projected to grow at a CAGR of 7.92% to reach US$4.504 billion by 2023, from US$2.851 billion in 2017.

    Artificial grasses are used in semi-arid and arid areas where climatic conditions are unfavorable for the growth of natural grass. These are increasingly being used in commercial and residential applications as the cost per square foot has become more competitive with traditional sod.

    Growing awareness among people regarding water conservation and increasing number of sports field and pitches around the globe are driving the artificial grass market growth. The market is expected to grow at a good pace owing to the higher adoption of artificial grass in various sports tournament.

    Major industry players profiled as part of the report are EasyTurf, SmartGrass, LLC, Heavenly Greens, DuPont, FieldTurf Inc., DP Turf, Victoria PLC, Matrix Turf, NURTEKS CARPET, and LIMONTA SPORT S.p.A.

    *Key Topics Covered*





    5.1. Nylon
    5.2. Polypropylene
    5.3. Polyester

    6.1. Sports Field
    6.2. Residential Landscape
    6.3. Rooftops
    6.4. Patios
    6.5. Commercial Venues
    6.6. Others

    7.1. North America
    7.2. South America
    7.3. Europe
    7.4. Middle East and Africa
    7.5. Asia Pacific

    8.1. Market Share Analysis
    8.2. Recent Investment and Deals
    8.3. Strategies of Key Players

    9.1. EasyTurf
    9.2. SmartGrass, LLC
    9.3. Heavenly Greens
    9.4. DuPont
    9.5. FieldTurf Inc.
    9.6. DP Turf
    9.7. Victoria PLC
    9.8. Matrix Turf
    9.9. Nurteks Carpet
    9.10. LIMONTA SPORT S.p.A

    For more information about this report visit

    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

    Laura Wood, Senior Press Manager
    For E.S.T Office Hours Call 1-917-300-0470
    For U.S./CAN Toll Free Call 1-800-526-8630
    For GMT Office Hours Call +353-1-416-8900
    Related Topics: Gardening Supplies and Equipment Reported by GlobeNewswire 6 hours ago.

    0 0

    Drugmaker Allergan Plc said on Wednesday it would take its textured breast implants off the market in Europe, a day after a French regulatory body ordered a recall of the implants, which have been linked to a rare form of cancer. Reported by Reuters India 6 hours ago.

    0 0

    British Prime Minister Theresa May has vowed to end free movement of people from Europe. Reported by SBS 6 hours ago.

    0 0

    Trial was final part of probe of suspected bribes paid to win contracts in Europe, north Africa and Asia Reported by 6 hours ago.

    0 0

    Viacom's MTV Russia has ordered reality series K-pop MTCamp, which will celebrate Korean popular music and will be Europe's first... Reported by 5 hours ago.

    0 0

    Cramo Plc  Stock Exchange Release 19 December 2018, at 22.00 (EET)

    *Cramo Board of Directors has decided to pursue towards separation of the Modular Space (Cramo Adapteo) business through a partial demerger*

    The Board of Directors of Cramo has concluded the assessment of strategic alternatives for the Modular Space business in order to release shareholder value.

    Based on the outcome of the assessment, the Board of Directors of Cramo has decided to pursue towards separation of the Company’s Modular Space business through a partial demerger. The transaction and separate listing of Cramo Adapteo is expected to take place in mid-2019.


    Leif Gustafsson
    President and CEO
    *Further information:
    Mr Leif Gustafsson, President and CEO, tel: +46 70 691 2550,
    Mr Aku Rumpunen, CFO, tel: +358 10 661 10, +358 40 556 3546,
    Mr Mattias Rådström, SVP, Communication, Marketing and Investor Relations, tel: +46 70 868 7045,
    Nasdaq Helsinki Ltd.
    Main media
    Cramo is Europe’s second largest rental services company specialising in construction machinery and equipment rental and rental-related services as well as the rental of modular space. Cramo operates in about 300 depots in fourteen countries. With a group staff around 2,500, Cramo's consolidated sales in 2017 was EUR 729.5 million. Cramo shares are listed on Nasdaq Helsinki Ltd.

    Cramo Adapteo is the sub-brand for Cramo’s modular space operations. 

    Read more:, Reported by GlobeNewswire 5 hours ago.

    0 0

    Rockville, MD, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Scholarships for Military Children and Heroes’ Legacy Scholarships programs for school year 2019-20 kicked off Dec. 14 and will continue accepting applications through Feb. 15.

    This marks the first time the application process will happen entirely online, making it easy to create an account, save work and submit applications.  All rules and requirements for the program, as well as links to frequently asked questions are available at

    *Scholarships for Military Children*

    Eligibility for the Scholarships for Military Children program is determined using the Defense Enrollment Eligibility Reporting System database. Applicants should ensure that they, as well as their sponsor, are enrolled in the DEERS database and have a current military dependent identification card.

    A total of 500 scholarship grants, each for $2,000, will be awarded for school year. There will be at least one recipient selected at every commissary location where qualified applications are received, and additional recipients will be selected based on a pro rata basis, so more applicants will be selected from those commissaries with larger numbers of applicants.

    The Scholarships for Military Children Program was created in recognition of the contributions of military families to the readiness of the fighting force and to celebrate the role of the commissary in the military family community. It is the intent of the program that a scholarship funded through contributions be awarded annually for each commissary operated by the Defense Commissary Agency worldwide.

    *Heroes’ Legacy Scholarships*

    The Heroes' Legacy Scholarships program honors not only those who have fallen in battle, but all who have died or have become disabled through their active military service since September 11, 2001. The program is open to their dependent unmarried children under age 23. A disability is defined as one that results in the service member being eligible for, and receiving, Traumatic Servicemembers' Group Life Insurance (TSGLI) or a permanent and total disability compensation rating of 100%.

    If a student or parent is not sure whether they qualify, they can submit documentation to Fisher House Foundation which will make such determinations on a case by case basis. Documentation should be sent via email to Please include "Heroes' Legacy Scholarships" in the subject line. If no response is provided within one week, please call Fisher House Foundation at (888) 294-8560 to ensure the email was received.

    The amount to be awarded each year depends on the amount of sponsorships and other donations designated for the Legacy Heroes' Scholarship program. Prior year recipients must reapply to be considered.

    *Scholarship Search Engine*

    Additionally, Fisher House Foundation has set up an extensive scholarship search engine tool for finding funding for you and your family whose service for our country qualifies you for these unique funding opportunities.  To try it out, go to:

    Good luck and God speed in your education endeavors.

    *About Fisher House Foundation*

    Fisher House Foundation is best known for a network of comfort homes where military and veterans’ families can stay at no cost while a loved one is receiving treatment.  These homes are located at major military and VA medical centers nationwide, and in Europe, close to the medical center or hospital it serves. Fisher Houses have up to 21 suites, with private bedrooms and baths.  Families share a common kitchen, laundry facilities, a warm dining room and an inviting living room.  Fisher House Foundation ensures that there is never a lodging fee.  Since inception, the program has saved military and veterans’ families an estimated $400+ million in out of pocket costs for lodging and transportation.

    Fisher House Foundation also operates the Hero Miles Program, using donated frequent flyer miles to bring family members to the bedside of injured service members as well as the Hotels for Heroes program using donated hotel points to allow family members to stay at hotels near medical centers without charge.  The Foundation also manages a grant program that supports other military charities and scholarship funds for military children, spouses and children of fallen and disabled veterans.


    · IMG_3502

    CONTACT: Brian Gawne
    Fisher House Foundation
    240.599.2462 Reported by GlobeNewswire 5 hours ago.

    0 0

    Largest number of investment rounds in Europe were in the UK despite Brexit concerns Reported by 4 hours ago.

    0 0

    For a long period of time, the energy transition was primarily a technical topic concerning the transformation of the energy grid. Technological developments and the decreasing costs of renewables have made it a viable alternative to fossil fuels. The integration, however, of these new systems requires considerable investments meaning money that directly or indirectly will be provided by ordinary citizens through taxes or their energy bill. In most parts of Europe, the energy transition is in full swing for a carbon neutral future. The EU has set… Reported by 4 hours ago.

    0 0

    ALPHARETTA, Ga., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced that it has submitted a New Drug Application (“NDA”) for XIPERE^TM to the U.S. Food and Drug Administration (“FDA”) for the treatment of macular edema associated with uveitis. The uveitis market is expected to grow by 2024 to nearly $550 million in the United States and over $1 billion globally.  Uveitis is a set of ocular inflammatory conditions and is one of the leading causes of vision loss worldwide, affecting approximately 350,000 patients in the United States and more than one million worldwide. Approximately one-third of these patients develop uveitic macular edema, a build-up of fluid in the macula, the area of the retina responsible for sharp, straight-ahead vision. Macular edema is the leading cause of vision loss and blindness in uveitis patients and can occur from uveitis affecting any anatomic location - anterior, intermediate, posterior or pan.

    If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis.

    “Based on the data from PEACHTREE, our pivotal Phase 3 clinical trial, we believe that XIPERE has the potential to become a new paradigm in the treatment of uveitic macular edema,” said Daniel White, Chief Executive Officer and President of Clearside. “PEACHTREE was the first clinical trial to demonstrate significant improvement in vision for patients with macular edema associated with non-infectious uveitis, and that improvement was achieved across all anatomical locations of uveitis. In addition, signs of inflammation resolved in more than two-thirds of patients treated with XIPERE across three commonly used measures of inflammation in the eye: vitreous haze; anterior chamber cells and anterior chamber flare. We have an experienced commercial team preparing for the potential launch of XIPERE and we also plan to submit applications for regulatory approval in select markets outside of the U.S.”

    *About XIPERE*

    XIPERE, Clearside’s first investigational treatment to reach NDA submission, is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the back of the eye via suprachoroidal injection into the space located between the choroid and the outer protective layer of the eye known as the sclera. Clearside’s proprietary suprachoroidal treatment approach is designed to enable rapid dispersion of medicine to the back of the eye, so that adequate medicine reaches and stays at the site of disease and has the potential to act longer, while minimizing harm to the surrounding healthy parts of the eye. This approach has potential to provide efficacy advantages and require fewer treatments.

    *About PEACHTREE*

    PEACHTREE, a randomized, masked, sham-controlled Phase 3 trial, enrolled 160 patients with macular edema associated with non-infectious uveitis, and compared XIPERE dosed every 12 weeks to sham control.

    The PEACHTREE trial met its primary endpoint, with 47% of patients in the XIPERE arm gaining at least 15 letters in best corrected visual acuity, as measured using the Early Treatment of Diabetic Retinopathy Study scale, from baseline at week 24, compared to 16% of patients in the sham control arm (p<.001 all key secondary and additional endpoints of the peachtree trial were also achieved.>
    *About Clearside*

    Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases. Clearside’s proprietary suprachoroidal treatment approach offers unprecedented access to the back of the eye where sight-threatening disease often occurs. The company’s unique platform for eye disease treatments is inherently flexible and intended to work with established medicines, new formulations of medicines, as well as future innovations such as gene therapy. Clearside is headquartered in Alpharetta, GA.  For more information, please visit Follow @clearsidebio on Twitter and Linkedin.

    *Cautionary Note Regarding Forward-Looking Statements*

    Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include expectations regarding the potential clinical development of Clearside’s product candidates, the availability of data from Clearside’s clinical trials, the timing of marketing authorization applications with regulatory agencies in Europe and other jurisdictions, and the potential commercialization of XIPERE, both in the United States and internationally. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in Clearside’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 16, 2018, Clearside’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, and Clearside’s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Clearside as of the date of this release, and Clearside assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.


    Stephen Kilmer
    Investor Relations
    (678) 430-8206

    Charles Deignan
    Chief Financial Officer
    678-270-4005 Reported by GlobeNewswire 4 hours ago.

older | 1 | .... | 1586 | 1587 | (Page 1588) | 1589 | 1590 | .... | 1652 | newer